BerGenBio – executive interview

BerGenBio – executive interview

Associated equity: BerGenBio

Edison Investment Research is terminating coverage on BerGenBio. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

BerGenBio — 1 video in collection

BerGenBio (BGBIO) is a clinical-stage biopharmaceutical company headquartered in Bergen, Norway with clinical development capabilities in Oxford, UK. It is a pioneer in AXL biology and is developing innovative drugs for aggressive diseases including immune-evasive, drug-resistant and metastatic cancers. Lead asset bemcentinib is being investigated for AML, NSCLC and COVID-19.

In this video, Martin Olin, BGBIO’s chief executive officer, provides an overview of the clinical activity for bemcentinib and outlines newsflow expected in the year ahead.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free